This is a 40-minute webinar dedicated to pharmacists. It described the pathophysiology of hypertension and the drugs used to treat this condition. The webinar features Dr. Edward Bengie Magsombol as speaker.
Duration: 40:49 min.
CPD Points: 0.5
Program Number: PROG-2024-75942
Telmisartan: Management of Hypertension and the Role of the Pharmacist by Dr. Edward-Bengie Magsombol Course Outline
What is Hypertension
How common is hypertension
Patients with controlled blood pressure
What causes hypertension?
The renin-angiotensin-aldosterone system
2018 ECS guidelines on hypertension
2020 Clinical Practice Guidelines for the Management of Hypertension in the Philippines
Drug-related causes of poor BP control
Angiotensin-converting enzyme inhibitors
Angiotensin receptor blockers
Angiotensin receptor blocker: Valsartan
Angiotensin receptor blocker: Irbesartan
Angiotensin receptor blocker: Losartan
Angiotensin receptor blocker: Telmisartan
Unique features of Telmisartan, by Boehringer Ingelheim
Advancement of Telmisartan in the Philippines
Single-pill combination: telmisartan + amlodipine
Efficacy: Telmisartan + amlodipine
Safety: Telmisartan + amlodipine
The role of the Philippine pharmacist in hypertension management
Effect of healthcare intervention on hypertension management
Who is the hypertensive patient at high risk?
RAAS inhibitors for high-risk hypertensive patients
Pathophysiology of hypertension and diabetes
2020 Philippine CPGs on hypertension
Losartan in patients with diabetes mellitus
Telmisartan is the only ARB proven and indicated to provide CV protection for high-risk patients 1-3 MALIIT SA TAAS
Pharmaceutical counselling
Hypertension and CKD: Related risk factors
Goals of hypertension treatment in chronic kidney disease